The potential link between GLP-1 therapies and gout risk is gaining attention as clinicians look beyond glucose control to broader metabolic outcomes. Patients with obesity and type 2 diabetes often face a dual burden of hyperuricemia and gout, yet these conditions are not always addressed in treatment plans. Could medications …
Read More »Stopping GLP-1 Therapy: New Data Highlight the Challenge of Weight Regain
Have you ever wondered why weight seems to come back so quickly after stopping a medication that once worked so well? Weight regain after GLP-1 therapy has become a growing concern as more patients discontinue treatments like semaglutide or liraglutide. While these medications are highly effective for weight loss and …
Read More »GLP-1 Therapy Before Surgery: New Guidance on Managing Aspiration Risk
As GLP-1 receptor agonists become more common in diabetes and weight management, new concerns are emerging around how GLP-1 medications are managed before surgery. What happens when a medication that slows digestion meets anesthesia? Increasingly, clinicians are asking whether continuing these therapies before surgery could raise aspiration risk. Clear protocols …
Read More »GLP-1 Drug Interactions: Why New Prescribing Patterns Are Raising Concerns
Concerns about GLP-1 drug interactions are rising as these therapies gain widespread use in diabetes and obesity management. As more patients start medications like semaglutide and liraglutide, clinicians are asking an important question: how do these drugs affect the absorption of other treatments? Much like slowing traffic on a busy …
Read More »Where Do GLP-1 Drugs Fit in Modern Diabetes Treatment? Rethinking the Therapy Algorithm
Managing type 2 diabetes today can feel like solving a moving puzzle. With so many therapies available, how do clinicians decide what comes next? GLP-1 therapies have become a key part of today’s diabetes treatment algorithm, helping providers balance glucose control, cardiovascular risk, and patient preferences. As treatment options evolve, …
Read More »GLP-1 Drugs and Cardiovascular Inflammation: A New Pathway for Risk Reduction?
Why do some patients still face heart risks even after managing blood sugar and cholesterol? This lingering issue has led researchers to explore how GLP-1 therapies may influence cardiovascular inflammation as a possible missing link. While traditional treatments focus on glucose and lipid control, growing evidence suggests inflammation may continue …
Read More »GLP-1 Adherence in the Real World: Why Patients Stop and How Clinicians Can Help
Staying consistent with GLP-1 therapy remains one of the biggest challenges in diabetes management today. While these therapies offer strong glycemic control, meaningful weight loss, and even cardiovascular benefits, many patients stop treatment earlier than expected. Why does that happen, and what can clinicians do differently? In many ways, GLP-1 …
Read More »GLP-1 Therapy and Sleep: Could Metabolic Drugs Improve Sleep Quality?
Researchers are beginning to explore how GLP-1 therapies may influence sleep, recovery, and overall metabolic health. Could a medication designed for blood sugar control also help patients sleep better? As surprising as it sounds, emerging evidence suggests a meaningful connection. This article looks at how GLP-1 receptor agonists may indirectly …
Read More »GLP-1 Drugs and Blood Pressure: Why These Diabetes Medications Lower More Than Glucose
When managing type 2 diabetes, most people focus on blood sugar. However, what if one medication could also improve heart health at the same time? That is exactly what researchers are discovering about how GLP-1 drugs affect blood pressure. These medications, originally designed to control glucose, are now showing consistent …
Read More »GLP-1s and CKD Progression: Are Anti-Inflammatory Effects Clinically Meaningful?
Chronic kidney disease (CKD) remains one of the most serious complications associated with diabetes, affecting millions of patients worldwide. While SGLT2 inhibitors have become foundational therapies for protecting kidney function, researchers are increasingly examining whether other drug classes may also slow renal decline. In particular, growing interest surrounds how GLP-1 …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.